REVELLEX

Revellex Adverse Events Reported to the FDA Over Time

How are Revellex adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Revellex, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Revellex is flagged as the suspect drug causing the adverse event.

Most Common Revellex Adverse Events Reported to the FDA

What are the most common Revellex adverse events reported to the FDA?

Death	27 (4.49%)
Infusion Related Reaction	24 (3.99%)
Tuberculosis	19 (3.16%)
Myocardial Infarction	11 (1.83%)
Dyspnoea	10 (1.66%)
Pneumonia	10 (1.66%)
Nausea	9 (1.5%)
Drug Ineffective	7 (1.16%)
Headache	7 (1.16%)
Dehydration	6 (1%)
Lupus-like Syndrome	6 (1%)
	Show More
Pyrexia	6 (1%)
Road Traffic Accident	6 (1%)
Sinusitis	6 (1%)
Arthralgia	5 (.83%)
Chest Pain	5 (.83%)
Diarrhoea	5 (.83%)
Disseminated Tuberculosis	5 (.83%)
Fatigue	5 (.83%)
Flushing	5 (.83%)
Lung Infection	5 (.83%)
Pruritus	5 (.83%)
Pulmonary Oedema	5 (.83%)
Sepsis	5 (.83%)
Urticaria	5 (.83%)
Abdominal Pain	4 (.67%)
Arthrodesis	4 (.67%)
Blood Glucose Increased	4 (.67%)
Blood Pressure Increased	4 (.67%)
Bone Graft	4 (.67%)
Bronchospasm	4 (.67%)
Cardiac Disorder	4 (.67%)
Colitis Ulcerative	4 (.67%)
Decreased Appetite	4 (.67%)
Diaphragmalgia	4 (.67%)
Diplopia	4 (.67%)
Discomfort	4 (.67%)
Drug Specific Antibody Present	4 (.67%)
Heart Rate Increased	4 (.67%)
Hip Arthroplasty	4 (.67%)
Hypersensitivity	4 (.67%)
Intestinal Stenosis	4 (.67%)
Large Intestinal Haemorrhage	4 (.67%)
Liver Function Test Abnormal	4 (.67%)
Malaise	4 (.67%)
Menorrhagia	4 (.67%)
Menstruation Irregular	4 (.67%)
Oxygen Saturation Decreased	4 (.67%)
Pulmonary Tuberculosis	4 (.67%)
Rectal Abscess	4 (.67%)
Restless Legs Syndrome	4 (.67%)
Subarachnoid Haemorrhage	4 (.67%)
Surgery	4 (.67%)
Vomiting	4 (.67%)
Accidental Overdose	3 (.5%)
Back Pain	3 (.5%)
Body Temperature Increased	3 (.5%)
Herpes Virus Infection	3 (.5%)
Hospitalisation	3 (.5%)
Hyperhidrosis	3 (.5%)
Intestinal Obstruction	3 (.5%)
Malignant Melanoma	3 (.5%)
Muscle Spasms	3 (.5%)
Oesophageal Candidiasis	3 (.5%)
Pain	3 (.5%)
Palpitations	3 (.5%)
Pneumonia Aspiration	3 (.5%)
Psoriasis	3 (.5%)
Rash	3 (.5%)
Renal Failure	3 (.5%)
Respiratory Failure	3 (.5%)
Rheumatoid Arthritis	3 (.5%)
Systemic Lupus Erythematosus	3 (.5%)
Tremor	3 (.5%)
Abasia	2 (.33%)
Adverse Event	2 (.33%)
Antibody Test Positive	2 (.33%)
Appendicitis Perforated	2 (.33%)
Atrial Flutter	2 (.33%)
Blood Creatinine Increased	2 (.33%)
Blood Sodium Increased	2 (.33%)
Bronchitis	2 (.33%)
Cardiac Arrest	2 (.33%)
Colectomy	2 (.33%)
Convulsion	2 (.33%)
Coronary Artery Disease	2 (.33%)
Cyanosis	2 (.33%)
Cytomegalovirus Infection	2 (.33%)
Deafness	2 (.33%)
Demyelination	2 (.33%)
Dystonia	2 (.33%)
Encephalitis	2 (.33%)
Erythema	2 (.33%)
Eye Swelling	2 (.33%)
Feeling Hot	2 (.33%)
Haemoglobin Decreased	2 (.33%)
Herpes Zoster	2 (.33%)
Hyperaesthesia	2 (.33%)
Hypoglycaemia	2 (.33%)
Hypotension	2 (.33%)
Hypovolaemic Shock	2 (.33%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Revellex, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Revellex is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Revellex

What are the most common Revellex adverse events reported to the FDA?

Infections - Pathogen Unspecified	51 (8.49%)
Mycobacterial Infectious	30 (4.99%)
Fatal Outcomes	28 (4.66%)
Administration Site Reactions	24 (3.99%)
Respiratory	24 (3.99%)
Gastrointestinal Signs	18 (3%)
Epidermal And Dermal Conditions	17 (2.83%)
Bone And Joint Therapeutic Procedur...	15 (2.5%)
Coronary Artery	13 (2.16%)
Joint	13 (2.16%)
Therapeutic And Nontherapeutic Effe...	11 (1.83%)
	Show More
Cardiac And Vascular Investigations	9 (1.5%)
Cardiac Disorder Signs	9 (1.5%)
Connective Tissue Disorders	9 (1.5%)
Injuries	9 (1.5%)
Lower Respiratory Tract Disorders	9 (1.5%)
Neurological	9 (1.5%)
Viral Infectious	9 (1.5%)
Menstrual Cycle And Uterine Bleedin...	8 (1.33%)
Metabolic, Nutritional And Blood Ga...	8 (1.33%)
Musculoskeletal And Connective Tiss...	8 (1.33%)
Gastrointestinal Stenosis And Obstr...	7 (1.16%)
Headaches	7 (1.16%)
Therapeutic Procedures And Supporti...	7 (1.16%)
Body Temperature Conditions	6 (1%)
Bronchial Disorders	6 (1%)
Electrolyte And Fluid Balance Condi...	6 (1%)
Fungal Infectious	6 (1%)
Gastrointestinal Inflammatory Condi...	6 (1%)
Gastrointestinal Therapeutic Proced...	6 (1%)
Movement Disorders	6 (1%)
Muscle	6 (1%)
Skin Neoplasms Malignant And Unspec...	6 (1%)
Vision	6 (1%)
Angiedema And Urticaria	5 (.83%)
Bacterial Infectious	5 (.83%)
Cardiac Arrhythmias	5 (.83%)
Gastrointestinal Hemorrhages	5 (.83%)
Gastrointestinal Motility And Defec...	5 (.83%)
Vascular	5 (.83%)
Allergic Conditions	4 (.67%)
Appetite And General Nutritional	4 (.67%)
Central Nervous System Infections A...	4 (.67%)
Central Nervous System Vascular	4 (.67%)
Decreased And Nonspecific Blood Pre...	4 (.67%)
Hepatobiliary	4 (.67%)
Physical Examination Topics	4 (.67%)
Seizures	4 (.67%)
Toxicology And Therapeutic Drug Mon...	4 (.67%)
Urinary Tract Signs	4 (.67%)
Bone And Joint Injuries	3 (.5%)
Bone Disorders	3 (.5%)
Immunology And Allergy	3 (.5%)
Medication Errors	3 (.5%)
Miscellaneous And Site Unspecified ...	3 (.5%)
Renal Disorders	3 (.5%)
Skin Appendage Conditions	3 (.5%)
Spinal Cord And Nerve Root	3 (.5%)
Spleen, Lymphatic And Reticulendoth...	3 (.5%)
Anemias Nonhemolytic And Marrow Dep...	2 (.33%)
Arteriosclerosis, Stenosis, Vascula...	2 (.33%)
Demyelinating	2 (.33%)
Encephalopathies	2 (.33%)
Eye	2 (.33%)
Gastrointestinal Vascular Condition...	2 (.33%)
Glucose Metabolism Disorders	2 (.33%)
Head And Neck Therapeutic Procedure...	2 (.33%)
Hearing	2 (.33%)
Hematology Investigations	2 (.33%)
Musculoskeletal And Connective Tiss...	2 (.33%)
Oral Soft Tissue Conditions	2 (.33%)
Pericardial	2 (.33%)
Pleural	2 (.33%)
Pulmonary Vascular	2 (.33%)
Renal And Urinary Tract Investigati...	2 (.33%)
Respiratory And Mediastinal Neoplas...	2 (.33%)
Synovial And Bursal	2 (.33%)
Upper Respiratory Tract Disorders	2 (.33%)
Vulvovaginal Disorders	2 (.33%)
Water, Electrolyte And Mineral	2 (.33%)
Abortions And Stillbirth	1 (.17%)
Anxiety Disorders	1 (.17%)
Cranial Nerve Disorders	1 (.17%)
Eye Therapeutic Procedures	1 (.17%)
Gastrointestinal Conditions	1 (.17%)
Hematological And Lymphoid Tissue T...	1 (.17%)
Hepatic And Hepatobiliary	1 (.17%)
Mental Impairment	1 (.17%)
Nephropathies	1 (.17%)
Nervous System Neoplasms Malignant ...	1 (.17%)
Peripheral Neuropathies	1 (.17%)
Procedural And Device Related Injur...	1 (.17%)
Renal And Urinary Tract Therapeutic...	1 (.17%)
Reproductive Neoplasms Male Maligna...	1 (.17%)
Tendon, Ligament And Cartilage	1 (.17%)
Tissue	1 (.17%)
Vascular Inflammations	1 (.17%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Revellex, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Revellex is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.